Beclomethasone_Dipropionate: profile and news

Oral Beclomethasone Dipropionate Controls Gastrointestinal Graft ... Feb 21, 2006
HONOLULU, HI -- February 21, 2006 -- Oral beclomethasone dipropionate (BDP) appears to be effective in controlling gastrointestinal graft versus host disease ... - DG News

DOR BioPharma Presents Positive New Survival Findings from Phase ... Feb 21, 2006
DOR BioPharma, Inc. (AMEX: DOR) ("DOR", or the "Company") announced today that survival results for orBec(R) (or oral beclomethasone dipropionate) from two ... - Genetic Engineering News,

DOR BioPharma Presents Positive New Survival Findings from Phase ... Feb 21, 2006
...(AMEX: DOR) ("DOR", or the "Company") announced today that survival results for orBec(R) (or oral beclomethasone dipropionate) from two randomized, double ... - Business Wire (press release),

orBec® Improves Survival in Patients with Intestinal Graft-Versus ... Feb 21, 2006
...annual Tandem Bone Marrow Transplant Meeting of the American Society of Hematology, the oral agent orBec® (oral beclomethasone dipropionate) improves survival ... - Cancer Consultants (press release),

DOR BioPharma Provides Financial Guidance and Update on European ... Feb 8, 2006
Our lead product, orBec(R) (oral beclomethasone dipropionate), is a potent, locally-acting corticosteroid being developed for the treatment of intestinal Graft ... - Genetic Engineering News,

DOR BioPharma Reports Positive New Survival Findings from ... Jan 20, 2006
...or the "Company") announced today that as part of its process to submit a New Drug Application ("NDA") for orBec(R) (oral beclomethasone dipropionate) for the ... - Business Wire (press release),

Breathe Deep Jan 20, 2006
...in the Department of Clinical Sciences and head of equine medicine and surgery, is investigating the efficacy of beclomethasone dipropionate for reducing ... - TheHorse.com,

Beximco Pharma begins exporting medicines to Sri Lanka Jan 20, 2006
The four generics of exported drugs are Azithrocin (Azithromycin), Decomit (Beclomethasone dipropionate), Cox B (celecoxib) and Deflux (Domperidone). ... - The New Nation,

Allergic rhinitis key to asthma control Dec 10, 2005
Stelmach and colleagues evaluated the effects of treatment with inhaled or topical nasal beclomethasone dipropionate (BDP), a steroid, given separately or in ... - Sydney Morning Herald (subscription),

DOR BioPharma Maintains AMEX Listing Dec 10, 2005
Our lead product, orBec(R) (oral beclomethasone dipropionate), is a potent, locally-acting corticosteroid being developed for the treatment of intestinal Graft ... - NAMC Newswire Releases (press release),

Dr. Chris Dale, Vice President, Technology, Cambrex ... Sep 15, 2005
Their lead product, orBec(R) (oral beclomethasone dipropionate), is a potent, locally-acting corticosteroid being developed for the treatment of intestinal ... - PR Newswire (press release),

FDA Approvals: Invader UGT1A1, SelectSecure Model 3830, Duet ... Aug 26, 2005
The lead also releases beclomethasone dipropionate for a short while after implantation to reduce postimplantation inflammation and improve tissue conduction. ... - Medscape (subscription)

A Review of Pregnancy Outcomes After Exposure to Orally Inhaled or ... Aug 12, 2005
A study that evaluated pregnancy outcomes in women with asthma who were treated with beclomethasone dipropionate similarly did not report any increase in the ... - RedNova.com,

DOR BioPharma and Dowpharma Enter Into a Joint Development ... Jul 26, 2005
Our lead product, orBec® (oral beclomethasone dipropionate), is a potent, locally-acting corticosteroid being developed for the treatment of intestinal Graft ... - Yahoo News (press release) <**results**>

Vaccine Researchers Combat Biothreat Agents; Preclinical Safety ... Jul 5, 2005
DOR's lead therapeutic product, orBec(R) (oral beclomethasone dipropionate), is a potent, locally-acting corticosteroid being developed for the treatment of ... - Business Wire (press release)

DOR BioPharma to Present at the Rodman & Renshaw Techvest 2nd ... Jun 13, 2005
Our lead product, orBec(R) (oral beclomethasone dipropionate), is a potent, locally-acting corticosteroid being developed for the treatment of intestinal Graft ... - Business Wire (press release),

DOR BioPharma to File NDA for orBec'R' Apr 20, 2005
DOR) ("DOR" or the "Company") announced its intention to file a new drug application (NDA) with the FDA for orBec(R) (oral beclomethasone dipropionate) for the ... - Business Wire

DOR's OrBec For Treating iGVHD Now On NDA Track Apr 20, 2005
The compound is an oral formulation of beclomethasone dipropionate, which has been marketed worldwide for more than 30 years as a nasal spray and in a metered ... - BioWorld Online (subscription)

DOR's Abstract Describing orBec Phase III Clinical Trial Results ... Apr 15, 2005
DOR's lead therapeutic product, orBec(R) (an oral formulation of beclomethasone dipropionate), is a potent, locally-acting corticosteroid being developed for ... - Business Wire

Once-Daily Alvesco Provides Comparable Relief of Asthma Symptoms ... Mar 29, 2005
...study, 404 adult patients with persistent asthma, who were receiving 400 - 500 ìg/day of the inhaled corticosteroid beclomethasone dipropionate or equivalent ... - Medical News Today,

DOR BioPharma Reports Fourth Quarter and Year End Financial ... Mar 14, 2005
DOR's lead therapeutic product, orBec(R) (an oral formulation of beclomethasone dipropionate), is a potent, locally-acting corticosteroid being developed for ... - Business Wire (press release),

Breathe Deep Mar 19, 2005
...in the Department of Clinical Sciences and head of equine medicine and surgery, is investigating the efficacy of beclomethasone dipropionate for reducing ... - TheHorse.com,

George A. Robertson, Ph.D. Joins DOR BioPharma as Vice President ... Mar 11, 2005
DOR's lead therapeutic product, orBec(R) (an oral formulation of beclomethasone dipropionate), is a potent, locally-acting corticosteroid being developed for ... - Business Wire (press release),